![Steven Knapper](https://profiles-cardiff.imgix.net/attachments/2484?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Professor Steven Knapper
(he/him)
- Media commentator
Teams and roles for Steven Knapper
Honorary Consultant Haematologist
Overview
I am an academic clinical haematologist, combining the role of professor within the Division of Cancer and Genetics at Cardiff University School of Medicine with clinical work as an Honorary Consultant Haematologist at the University Hospital of Wales (Cardiff & Vale University Health Board) where I currently act as haematological cancer lead and lead early phase haematological cancer trials and the regional acute leukaemia service.
My clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia and the myeloproliferative neoplasms. My chief research interest lies in the development of targeted therapeutic agents in myeloid malignancies; this includes both pre-clinical laboratory studies and clinical research including 'back to bench' laboratory projects running alongside clinical trials.
I am extensively involved in the development of clinical research at a national level through membership of the UK NCRI AML and Myeloproliferative Neoplasms Clinical Study Groups. I am currently co-chief investigator of the AML18 trial. My other roles include Deputy Medical Director of the UK Trials Acceleration Programme, Associate Director of the Wales Cancer Research Centre and lead of Cardiff University School of Medicine medical undergraduate haematology teaching.
Publication
2025
- Brierley, C. K. et al., 2025. Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A. Nature Genetics 57 (6), pp.1478-1492. (10.1038/s41588-025-02190-6)
- Knapper, S. et al. 2025. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood (10.1182/blood.2025031006)
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
- Van Der Maas, N. G. et al., 2025. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Advances 9 (15), pp.3853-3864. (10.1182/bloodadvances.2025015797)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
- Wood, H. et al., 2025. Venetoclax‐based non‐intensive combinations for relapsed/refractory acute myeloid leukaemia—Real‐world data from a UK‐wide programme [Research Letter]. British Journal of Haematology 207 (1), pp.254-259. (10.1111/bjh.20149)
2024
- Brunner, A. M. et al., 2024. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM?3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. American Journal of Hematology 99 (2), pp.E32-E36. (10.1002/ajh.27161)
- Jimenez-Chillon, C. et al., 2024. Venetoclax-based low intensity therapy in molecular failure of NPM1 mutated AML. Blood Advances 8 (2), pp.343-352. (10.1182/bloodadvances.2023011106)
- Russell, N. H. et al., 2024. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations. Journal of Clinical Oncology 42 (10), pp.1158-1168. (10.1200/JCO.23.00943)
- Versluis, J. et al., 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34), pp.4084-4094. (10.1200/JCO.23.02631)
2023
- Fang, Z. et al., 2023. Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. Nature Communications 14 7725. (10.1038/s41467-023-43175-5)
- Freeman, S. D. et al., 2023. Fractionated versus single dose Gemtuzumab Ozogamicin with determinants of benefit in older AML: UK NCRI AML18 Trial. Blood 142 (20), pp.1697-1707. (10.1182/blood.2023020630)
- Harrison, C. N. et al., 2023. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. Journal of Clinical Oncology 41 (19), pp.3534-3544. (10.1200/JCO.22.01935)
- Iland, H. J. et al., 2023. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances 7 (11), pp.2580-2585. (10.1182/bloodadvances.2022007126)
- Mehta, P. et al., 2023. Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. British Journal of Haematology 200 (2), pp.150-159. (10.1111/bjh.18516)
- Mussai, F. et al., 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200 (5), pp.573-578. (10.1111/bjh.18560)
- Othman, J. et al., 2023. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia 37 (10), pp.2066-2072. (10.1038/s41375-023-01994-x)
- Othman, J. et al., 2023. A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Advances 7 (16), pp.4539-4549. (10.1182/bloodadvances.2023010276)
- Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37 , pp.276-287. (10.1038/s41375-022-01801-z)
- Russell, N. et al., 2023. P484: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19v2 "Midotarg" Pilot Trial. HemaSphere 7 (S3) e13145db. (10.1097/01.HS9.0000968844.13145.db)
2022
- Dillon, R. et al., 2022. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer 22 1174. (10.1186/s12885-022-10221-2)
- Freeman, S. D. et al., 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140 (S1), pp.532-533. (10.1182/blood-2022-162245)
- Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12 840046. (10.3389/fonc.2022.840046)
- Othman, J. et al., 2022. Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial. Presented at: 64th ASH Annual Meeting and Exposition New Orleans, Louisiana 10-13 December 2022. Vol. 140.Vol. S1. American Society of Hematology. , pp.1036-1038. (10.1182/blood-2022-159433)
- Russell, N. H. et al., 2022. FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140 (S1), pp.526-528. (10.1182/blood-2022-162377)
- Wood, H. et al., 2022. Venetoclax-based non-intensive combinations successfully salvage molecular relapse of acute myeloid leukemia and are an important bridge to cellular therapy in relapsed/refractory disease - real-world data from a UK-wide programme. Blood 140 (S1), pp.9016-9018. (10.1182/blood-2022-167097)
2021
- Burnett, A. K. et al. 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39 (8), pp.890-901. (10.1200/JCO.20.01170)
- Dennis, M. et al., 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5 (24), pp.5621-5625. (10.1182/bloodadvances.2021005038)
- Montesinos, P. et al., 2021. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia 35 (1), pp.62–74. (10.1038/s41375-020-0773-5)
- Peterlin, P. et al., 2021. FLT3 ligand in acute myeloid leukemia: a simple test with deep implications. Leukemia & Lymphoma 62 (2), pp.264-270. (10.1080/10428194.2020.1834091)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
- Salisbury, R. A. et al., 2021. Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. Leukemia 35 , pp.2424-2430. (10.1038/s41375-021-01143-2)
2020
- Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34 (2), pp.427-440. (10.1038/s41375-019-0596-4)
- Hogan, F. L. , Williams, V. and Knapper, S. 2020. FLT3 Inhibition in acute myeloid leukaemia - current knowledge and future prospects. Current Cancer Drug Targets 20 (7), pp.513-531. (10.2174/1570163817666200518075820)
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191 (2), pp.231-242. (10.1111/bjh.16665)
2019
- Legge, S. E. et al. 2019. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Molecular Psychiatry 24 , pp.328-337. (10.1038/s41380-018-0335-7)
- McMullin, M. F. et al., 2019. A guideline for the diagnosis and management of polycythaemia vera. British Journal of Haematology 184 (2), pp.176-191. (10.1111/bjh.15648)
- Milne, P. et al., 2019. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances 3 (20), pp.3052-3061. (10.1182/bloodadvances.2019000197)
2018
- Burnett, A. K. et al. 2018. Addition of the mammalian target of rapamycin inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial. Haematologica 103 (10), pp.1654-1661. (10.3324/haematol.2018.189514)
2017
- Butt, N. M. et al., 2017. Guideline for the investigation and management of eosinophilia. British Journal of Haematology 176 (4), pp.553-572. (10.1111/bjh.14488)
- Harrison, C. N. et al., 2017. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 130 (17), pp.1889-1897. (10.1182/blood-2017-05-785790)
- Khan, N. et al., 2017. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia 31 , pp.1059-1068. (10.1038/leu.2016.309)
- Knapper, S. et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9), pp.1143-1154. (10.1182/blood-2016-07-730648)
- Williams, J. et al., 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology 178 (2), pp.240-249.
2016
- Beauverd, Y. et al., 2016. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica 101 (5), pp.e182-e184. (10.3324/haematol.2015.139691)
- Khan, N. et al., 2016. Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCl2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia. PLOS ONE 11 (9) e0163291. (10.1371/journal.pone.0163291)
- Zabkiewicz, J. et al. 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7 (13), pp.16650-16662. (10.18632/oncotarget.7692)
2015
- Burnett, A. K. et al., 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology 16 (13), pp.1295-1305. (10.1016/S1470-2045(15)00193-X)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
- Knapper, S. 2015. The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia. Haematologica 100 (9), pp.1105-1107. (10.3324/haematol.2015.134023)
- Mead, A. J. et al., 2015. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. British Journal of Haematology 170 (1), pp.29-39. (10.1111/bjh.13379)
2014
- Andersen, C. L. et al., 2014. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research 38 (7), pp.816-821. (10.1016/j.leukres.2014.04.002)
- Knapper, S. et al. 2014. Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Leukemia Research 38 (3), pp.346-351. (10.1016/j.leukres.2013.12.011)
- Reilly, J. T. et al., 2014. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. British Journal of Haematology 167 (3), pp.418-420. (10.1111/bjh.12985)
2013
- Andersen, C. L. et al., 2013. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology 162 (4), pp.498-508. (10.1111/bjh.12416)
- Burnett, A. K. et al. 2013. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122 (8), pp.1384-1394. (10.1182/blood-2013-04-496596)
- Craddock, C. et al., 2013. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27 (5), pp.1028-1036. (10.1038/leu.2012.312)
- Moore, A. S. et al., 2013. Novel therapies for children with acute myeloid leukaemia. Leukemia 27 (7), pp.1451-1460. (10.1038/leu.2013.106)
- Walsby, E. J. et al. 2013. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology 161 (1), pp.57-67. (10.1111/bjh.12215)
2012
- Reilly, J. T. et al., 2012. Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology 158 (4), pp.453-471. (10.1111/j.1365-2141.2012.09179.x)
- Taylor, P. R. et al. 2012. Development of myeloproliferative disease in 12/15-lipoxygenase deficiency [Letter]. Blood 119 (25), pp.6173-6174. (10.1182/blood-2012-02-410928)
2011
- Dijk, M. v. et al., 2011. The proteasome inhibitor bortezomib sensitizes AML with myelomonocytic differentiation to TRAIL mediated apoptosis. Cancers 3 (4), pp.1329-1350. (10.3390/cancers3011329)
- Goardon, N. et al., 2011. Coexistence Of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19 (1), pp.138-152. (10.1016/j.ccr.2010.12.012)
- Knapper, S. 2011. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opinion on Investigational Drugs 20 (10), pp.1377-1395. (10.1517/13543784.2011.611802)
- Knapper, S. et al. 2011. The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials. Blood -New York- 118 (21), pp.194-194.
- Moore, C. et al., 2011. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. International Journal of Infectious Diseases 203 (1), pp.18-24. (10.1093/infdis/jiq007)
- Sato, T. et al., 2011. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117 (12), pp.3286-3293. (10.1182/blood-2010-01-266742)
- Szegezdi, E. et al., 2011. Targeting AML through DR4 with a novel variant of rhTRAIL. Journal of Cellular and Molecular Medicine 15 (10), pp.2216-2231. (10.1111/j.1582-4934.2010.01211.x)
- Walsby, E. J. et al. 2011. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 96 (3), pp.393-399. (10.3324/haematol.2010.032680)
2009
- Burnett, A. K. and Knapper, S. 2009. Acute myeloid leukaemia. In: Treleaven, J. G. and Barrett, A. J. eds. Hematopoietic Stem Cell Transplantation in Clinical Practice. Edinburgh: Churchill Livingstone Elsevier. , pp.25-34.
- Knapper, S. et al. 2009. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may Influence relapse risk. Blood -New York- 114 (22), pp.326-326.
2008
- Hewamana, S. et al. 2008. IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia. International Journal of Hematology 88 (4), pp.424-427. (10.1007/s12185-008-0179-z)
2007
- Burnett, A. K. and Knapper, S. 2007. Targeting treatment in AML. Hematology: American Society of Haematology Education Program Book 2007 (1), pp.429-434. (10.1182/asheducation-2007.1.429)
- Knapper, S. 2007. FLT3 inhibition in acute myeloid leukaemia. British Journal of Haematology 138 (6), pp.687-699. (10.1111/j.1365-2141.2007.06700.x)
2006
- Knapper, S. et al. 2006. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (10), pp.3262-3270. (10.1182/blood-2006-04-015560)
- Knapper, S. et al. 2006. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108 (10), pp.3494-3503. (10.1182/blood-2006-04-015487)
Articles
- Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34 (2), pp.427-440. (10.1038/s41375-019-0596-4)
- Andersen, C. L. et al., 2013. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology 162 (4), pp.498-508. (10.1111/bjh.12416)
- Andersen, C. L. et al., 2014. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research 38 (7), pp.816-821. (10.1016/j.leukres.2014.04.002)
- Beauverd, Y. et al., 2016. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica 101 (5), pp.e182-e184. (10.3324/haematol.2015.139691)
- Brierley, C. K. et al., 2025. Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A. Nature Genetics 57 (6), pp.1478-1492. (10.1038/s41588-025-02190-6)
- Brunner, A. M. et al., 2024. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM?3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. American Journal of Hematology 99 (2), pp.E32-E36. (10.1002/ajh.27161)
- Burnett, A. K. et al. 2018. Addition of the mammalian target of rapamycin inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial. Haematologica 103 (10), pp.1654-1661. (10.3324/haematol.2018.189514)
- Burnett, A. K. et al., 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology 16 (13), pp.1295-1305. (10.1016/S1470-2045(15)00193-X)
- Burnett, A. K. et al. 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39 (8), pp.890-901. (10.1200/JCO.20.01170)
- Burnett, A. K. and Knapper, S. 2007. Targeting treatment in AML. Hematology: American Society of Haematology Education Program Book 2007 (1), pp.429-434. (10.1182/asheducation-2007.1.429)
- Burnett, A. K. et al. 2013. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122 (8), pp.1384-1394. (10.1182/blood-2013-04-496596)
- Butt, N. M. et al., 2017. Guideline for the investigation and management of eosinophilia. British Journal of Haematology 176 (4), pp.553-572. (10.1111/bjh.14488)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
- Craddock, C. et al., 2013. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27 (5), pp.1028-1036. (10.1038/leu.2012.312)
- Dennis, M. et al., 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5 (24), pp.5621-5625. (10.1182/bloodadvances.2021005038)
- Dijk, M. v. et al., 2011. The proteasome inhibitor bortezomib sensitizes AML with myelomonocytic differentiation to TRAIL mediated apoptosis. Cancers 3 (4), pp.1329-1350. (10.3390/cancers3011329)
- Dillon, R. et al., 2022. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer 22 1174. (10.1186/s12885-022-10221-2)
- Fang, Z. et al., 2023. Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. Nature Communications 14 7725. (10.1038/s41467-023-43175-5)
- Freeman, S. D. et al., 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140 (S1), pp.532-533. (10.1182/blood-2022-162245)
- Freeman, S. D. et al., 2023. Fractionated versus single dose Gemtuzumab Ozogamicin with determinants of benefit in older AML: UK NCRI AML18 Trial. Blood 142 (20), pp.1697-1707. (10.1182/blood.2023020630)
- Goardon, N. et al., 2011. Coexistence Of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19 (1), pp.138-152. (10.1016/j.ccr.2010.12.012)
- Harrison, C. N. et al., 2017. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 130 (17), pp.1889-1897. (10.1182/blood-2017-05-785790)
- Harrison, C. N. et al., 2023. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. Journal of Clinical Oncology 41 (19), pp.3534-3544. (10.1200/JCO.22.01935)
- Hewamana, S. et al. 2008. IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia. International Journal of Hematology 88 (4), pp.424-427. (10.1007/s12185-008-0179-z)
- Hogan, F. L. , Williams, V. and Knapper, S. 2020. FLT3 Inhibition in acute myeloid leukaemia - current knowledge and future prospects. Current Cancer Drug Targets 20 (7), pp.513-531. (10.2174/1570163817666200518075820)
- Iland, H. J. et al., 2023. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances 7 (11), pp.2580-2585. (10.1182/bloodadvances.2022007126)
- Jimenez-Chillon, C. et al., 2024. Venetoclax-based low intensity therapy in molecular failure of NPM1 mutated AML. Blood Advances 8 (2), pp.343-352. (10.1182/bloodadvances.2023011106)
- Khan, N. et al., 2017. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia 31 , pp.1059-1068. (10.1038/leu.2016.309)
- Khan, N. et al., 2016. Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCl2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia. PLOS ONE 11 (9) e0163291. (10.1371/journal.pone.0163291)
- Knapper, S. 2007. FLT3 inhibition in acute myeloid leukaemia. British Journal of Haematology 138 (6), pp.687-699. (10.1111/j.1365-2141.2007.06700.x)
- Knapper, S. 2011. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opinion on Investigational Drugs 20 (10), pp.1377-1395. (10.1517/13543784.2011.611802)
- Knapper, S. 2015. The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia. Haematologica 100 (9), pp.1105-1107. (10.3324/haematol.2015.134023)
- Knapper, S. et al. 2006. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (10), pp.3262-3270. (10.1182/blood-2006-04-015560)
- Knapper, S. et al. 2009. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may Influence relapse risk. Blood -New York- 114 (22), pp.326-326.
- Knapper, S. et al. 2014. Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Leukemia Research 38 (3), pp.346-351. (10.1016/j.leukres.2013.12.011)
- Knapper, S. et al. 2025. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood (10.1182/blood.2025031006)
- Knapper, S. et al. 2006. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108 (10), pp.3494-3503. (10.1182/blood-2006-04-015487)
- Knapper, S. et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9), pp.1143-1154. (10.1182/blood-2016-07-730648)
- Knapper, S. et al. 2011. The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials. Blood -New York- 118 (21), pp.194-194.
- Legge, S. E. et al. 2019. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Molecular Psychiatry 24 , pp.328-337. (10.1038/s41380-018-0335-7)
- McMullin, M. F. et al., 2019. A guideline for the diagnosis and management of polycythaemia vera. British Journal of Haematology 184 (2), pp.176-191. (10.1111/bjh.15648)
- Mead, A. J. et al., 2015. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. British Journal of Haematology 170 (1), pp.29-39. (10.1111/bjh.13379)
- Mehta, P. et al., 2023. Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. British Journal of Haematology 200 (2), pp.150-159. (10.1111/bjh.18516)
- Milne, P. et al., 2019. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances 3 (20), pp.3052-3061. (10.1182/bloodadvances.2019000197)
- Montesinos, P. et al., 2021. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia 35 (1), pp.62–74. (10.1038/s41375-020-0773-5)
- Moore, A. S. et al., 2013. Novel therapies for children with acute myeloid leukaemia. Leukemia 27 (7), pp.1451-1460. (10.1038/leu.2013.106)
- Moore, C. et al., 2011. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. International Journal of Infectious Diseases 203 (1), pp.18-24. (10.1093/infdis/jiq007)
- Mussai, F. et al., 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200 (5), pp.573-578. (10.1111/bjh.18560)
- Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12 840046. (10.3389/fonc.2022.840046)
- Othman, J. et al., 2023. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia 37 (10), pp.2066-2072. (10.1038/s41375-023-01994-x)
- Othman, J. et al., 2023. A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Advances 7 (16), pp.4539-4549. (10.1182/bloodadvances.2023010276)
- Peterlin, P. et al., 2021. FLT3 ligand in acute myeloid leukemia: a simple test with deep implications. Leukemia & Lymphoma 62 (2), pp.264-270. (10.1080/10428194.2020.1834091)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
- Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37 , pp.276-287. (10.1038/s41375-022-01801-z)
- Reilly, J. T. et al., 2012. Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology 158 (4), pp.453-471. (10.1111/j.1365-2141.2012.09179.x)
- Reilly, J. T. et al., 2014. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. British Journal of Haematology 167 (3), pp.418-420. (10.1111/bjh.12985)
- Russell, N. et al., 2023. P484: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19v2 "Midotarg" Pilot Trial. HemaSphere 7 (S3) e13145db. (10.1097/01.HS9.0000968844.13145.db)
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
- Russell, N. H. et al., 2022. FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140 (S1), pp.526-528. (10.1182/blood-2022-162377)
- Russell, N. H. et al., 2024. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations. Journal of Clinical Oncology 42 (10), pp.1158-1168. (10.1200/JCO.23.00943)
- Salisbury, R. A. et al., 2021. Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. Leukemia 35 , pp.2424-2430. (10.1038/s41375-021-01143-2)
- Sato, T. et al., 2011. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117 (12), pp.3286-3293. (10.1182/blood-2010-01-266742)
- Szegezdi, E. et al., 2011. Targeting AML through DR4 with a novel variant of rhTRAIL. Journal of Cellular and Molecular Medicine 15 (10), pp.2216-2231. (10.1111/j.1582-4934.2010.01211.x)
- Taylor, P. R. et al. 2012. Development of myeloproliferative disease in 12/15-lipoxygenase deficiency [Letter]. Blood 119 (25), pp.6173-6174. (10.1182/blood-2012-02-410928)
- Van Der Maas, N. G. et al., 2025. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Advances 9 (15), pp.3853-3864. (10.1182/bloodadvances.2025015797)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
- Versluis, J. et al., 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34), pp.4084-4094. (10.1200/JCO.23.02631)
- Walsby, E. J. et al. 2011. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 96 (3), pp.393-399. (10.3324/haematol.2010.032680)
- Walsby, E. J. et al. 2013. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology 161 (1), pp.57-67. (10.1111/bjh.12215)
- Williams, J. et al., 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology 178 (2), pp.240-249.
- Wood, H. et al., 2022. Venetoclax-based non-intensive combinations successfully salvage molecular relapse of acute myeloid leukemia and are an important bridge to cellular therapy in relapsed/refractory disease - real-world data from a UK-wide programme. Blood 140 (S1), pp.9016-9018. (10.1182/blood-2022-167097)
- Wood, H. et al., 2025. Venetoclax‐based non‐intensive combinations for relapsed/refractory acute myeloid leukaemia—Real‐world data from a UK‐wide programme [Research Letter]. British Journal of Haematology 207 (1), pp.254-259. (10.1111/bjh.20149)
- Zabkiewicz, J. et al. 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7 (13), pp.16650-16662. (10.18632/oncotarget.7692)
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191 (2), pp.231-242. (10.1111/bjh.16665)
Book sections
- Burnett, A. K. and Knapper, S. 2009. Acute myeloid leukaemia. In: Treleaven, J. G. and Barrett, A. J. eds. Hematopoietic Stem Cell Transplantation in Clinical Practice. Edinburgh: Churchill Livingstone Elsevier. , pp.25-34.
Conferences
- Othman, J. et al., 2022. Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial. Presented at: 64th ASH Annual Meeting and Exposition New Orleans, Louisiana 10-13 December 2022. Vol. 140.Vol. S1. American Society of Hematology. , pp.1036-1038. (10.1182/blood-2022-159433)
Biography
Education and Qualifications
2006 DM (Christ Church, Oxford)
2006 FRCPath (Royal College of Pathologists)
1999 MRCP (Royal College of Physicians – London)
1996 BMBCh (Christ Church, Oxford)
1993 BA / MA (Hons) (Trinity College, Cambridge)
Career Overview
2021- Present: Professor, Cardiff University School of Medicine and Honorary Consultant Haematologist (Cardiff & Vale University Health Board)
2016 - 2021: Clinical Reader in Haematology (Cardiff University Schoold of Medicine) and Honorary Consultant Haematologist (C&V UHB)
2007 - 2016: Clinical Senior Lecturer in Haematology (Cardiff University) and Honorary Consultant Haematologist (C&V UHB)
2004 - 2007: Clinical Lecturer in Haematology (Cardiff University)
2001- 2006: Specialist Registar in Haematology (All Wales Higher Training Programme)
Professional memberships
Fellow of Royal College of Pathologists
Member of Royal College of Physicians (London)
UK NCRN Acute Myeloid Leukaemia Clinical Study Group
UK NCRN Myeloproliferative Neoplasms Clinical Study Group
British Society for Haematology
American Society of Hematology
